Welcome to our dedicated page for Varex Imaging SEC filings (Ticker: VREX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Varex Imaging Corporation (VREX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a publicly traded Nasdaq issuer. Varex designs and manufactures X-ray imaging components and systems for medical, industrial, and security applications, and its filings offer detailed insight into how this business is reflected in its financial statements, risk factors, and governance disclosures.
Through this page, users can review Varex’s periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which present segment information for the Medical and Industrial businesses, revenue composition, gross margin, operating expenses including research and development, and details on capital structure items like long-term debt and convertible notes. These filings also contain management’s discussion and analysis and other disclosures that complement the high-level figures in press releases.
Current reports on Form 8-K document specific material events. For example, a recent 8-K furnished an earnings press release titled “Varex Announces Financial Results for Fourth Quarter and Fiscal Year 2025,” while another 8-K described a transition agreement with the company’s Senior Vice President, Chief Legal Officer, and Corporate Secretary, outlining continued service, compensation, and equity vesting terms. Such filings help investors track both financial performance and key governance changes.
On Stock Titan, VREX filings are updated as they are made available through EDGAR. AI-powered summaries highlight the main points of lengthy documents, helping readers quickly understand topics such as segment performance, non-GAAP reconciliations, debt and liquidity, and executive arrangements. Users can also review ownership and insider activity through forms that report transactions by officers and directors, providing an additional perspective on Varex Imaging Corporation’s regulatory record.
Varex Imaging Corp's Chief Financial Officer reported multiple equity transactions in company stock. On 12/10/2025, restricted stock units converted into 7,063 and 13,966 shares of common stock, consistent with the one-for-one RSU terms. To cover tax obligations, 5,227 shares were disposed of at $11.7 per share, leaving 106,891 shares of common stock directly owned.
The report also shows a new grant of 58,333 restricted stock units, scheduled to vest 50% on December 10, 2027 and 50% on December 10, 2029, along with earlier RSU awards that continue to vest on their original schedules.
Varex Imaging Corporation (VREX) filed its annual report describing a global business focused on X-ray tubes, flat panel and photon counting detectors, software and related components used in medical, security and industrial inspection systems. The company operates two segments, Medical and Industrial, and works mainly with large OEM customers. As of April 4, 2025, non-affiliate market value was about $339.3 million, and as of November 11, 2025 there were 41.7 million common shares outstanding. Varex highlights revenue concentration, with its top five customers providing about 40% of 2025 revenue and Canon alone about 18%. The report also emphasizes extensive global regulation, trade and tariff exposure, especially in China, and notes MOFCOM investigations into imported CT X-ray tubes that affect roughly 10% of total revenue.
Varex Imaging Corporation (VREX) filed a current report to announce that it has released a press release with its preliminary operating results for the twelve months ended October 3, 2025. The press release, titled “Varex Announces Financial Results for Fourth Quarter and Fiscal Year 2025,” is furnished as Exhibit 99.1 to the report and provides details on the company’s fourth quarter and full fiscal year 2025 performance. The company specifies that this information is being furnished under the securities laws rather than formally filed, which affects how it may be used in other regulatory documents.
Varex Imaging (VREX) insider filing: The company’s Chief Legal Officer filed an initial ownership report on Form 3. The filing states no securities are beneficially owned and lists an amount of 0 shares. The date of the event requiring the statement is 10/06/2025. This is a routine disclosure establishing insider reporting status.
Dimensional Fund Advisors LP filed an amended Schedule 13G reporting ownership of 1,992,611 shares of Varex Imaging Corp common stock, representing 4.8% of the outstanding class. The filing states these shares are owned by investment funds advised or sub‑advised by Dimensional and that Dimensional disclaims beneficial ownership of the shares while acknowledging it may possess voting and/or investment power as adviser. Of the reported shares, 1,951,986 shares are listed as sole voting power and 1,992,611 as sole dispositive power. The filing affirms the holdings were acquired in the ordinary course of business and not for the purpose of changing or influencing control.
Insider sale by Varex Imaging Corp officer under a pre-established plan. Karen L. Aranki, Chief Human Resources Officer and a company officer, reported the sale of 3,174 shares of Varex Imaging common stock on 09/19/2025 at an average price of $12.34 per share. After the transaction she beneficially owned 177 shares. The filing states the sales were effected pursuant to a 10b5-1 trading plan adopted June 17, 2025, indicating these trades followed an established written arrangement rather than ad hoc decisions. The Form 4 is signed and dated 09/22/2025.
Insider sale by Varex Imaging Corp officer under a pre-established plan. Karen L. Aranki, Chief Human Resources Officer and a company officer, reported the sale of 3,174 shares of Varex Imaging common stock on 09/19/2025 at an average price of $12.34 per share. After the transaction she beneficially owned 177 shares. The filing states the sales were effected pursuant to a 10b5-1 trading plan adopted June 17, 2025, indicating these trades followed an established written arrangement rather than ad hoc decisions. The Form 4 is signed and dated 09/22/2025.
Varex Imaging Corp (VREX) filed a Form 144 reporting a proposed sale of 3,174 common shares held by a person whose restricted stock vested on 05/15/2025. The shares are to be sold through Fidelity Brokerage Services LLC on or about 09/19/2025 on the NASDAQ, with an aggregate market value reported as $39,167.16. The filer indicates the shares were acquired as compensation upon vesting and reports no other sales in the past three months. The filing includes the standard Rule 144 representation that the seller is not aware of undisclosed material adverse information.
Varex Imaging Corp (VREX) filed a Form 144 reporting a proposed sale of 3,174 common shares held by a person whose restricted stock vested on 05/15/2025. The shares are to be sold through Fidelity Brokerage Services LLC on or about 09/19/2025 on the NASDAQ, with an aggregate market value reported as $39,167.16. The filer indicates the shares were acquired as compensation upon vesting and reports no other sales in the past three months. The filing includes the standard Rule 144 representation that the seller is not aware of undisclosed material adverse information.
Varex Imaging Corporation reported that Kimberley Honeysett, its Senior Vice President, Chief Legal Officer, and Corporate Secretary, has agreed to transition out of the Chief Legal Officer role. She will remain CLO through October 3, 2025, then continue providing transition services as a non-executive employee or advisor through December 12, 2027, reporting to the Chief Executive Officer.
During the transition period, she will continue to receive her current salary, benefits, and, for fiscal year 2026, eligibility for a management incentive plan bonus. For the remainder of the continued service period, she will receive $100,000 in compensation, continued health insurance coverage, and other benefits described in her transition agreement, and will continue vesting in existing equity awards but will not receive new equity grants. The agreement also includes mutual releases, indemnification, and allows the company to terminate the arrangement for cause.
Jay K. Kunkel, a director of Varex Imaging Corp (VREX), sold 3,000 shares of the company's common stock on 08/14/2025 at $10.49 per share. After the sale, he beneficially owned 19,477 shares, reported as direct ownership. The Form 4 disclosure records the transaction and the sale price for each share.
The filing provides a straightforward record of insider liquidity: a director reduced his stake by 3,000 shares while maintaining a mid-sized direct holding in the company. No options, derivative transactions, or other compensatory arrangements are reported.
Varex Imaging Corporation (VREX) Form 144 filing: An insider proposes to sell 3,000 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $31,470. The shares represent restricted stock that vested and were acquired on 02/13/2023 as compensation. The sale is scheduled for approximately 08/14/2025 on NASDAQ. The filer reports 41,500,000 shares outstanding for this class. The filer also disclosed a prior sale of 2,575 shares on 06/18/2025 for gross proceeds of $20,007.75. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.